Keep reading to learn about the common, mild, and serious side effects Enhertu can cause. For a general overview of the drug, including details about its uses, dosage, and cost, see this Enhertu ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Enhertu is supplied in a single-dose vial containing 100mg of lyophilized powder for reconstitution and further dilution prior to IV infusion. Patients should be selected for treatment with ...

Enhertu belongs to a class of medicines called ... during treatment and for four to seven months after the last dose.

The dose escalation portion of the trial enrolled ... The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Top-line data from the study showed that people treated with amycretin experienced a weight loss of 9.7% for the 1.25 mg dose over 20 weeks ... AZN & Daiichi’s Enhertu for Expanded Breast ...

An analysis of data from the 447-patient KEYFORM-007 study revealed that the fixed-dose combination of Keytruda ... of AstraZeneca and Daiichi Sankyo's Enhertu.

Zongertinib met its primary objective, with an objective response rate of 66.7% and a low rate (3%) of treatment discontinuations due to toxicity in the NSCLC group given the dose selected for the ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

For years, Linda Nolan was open about the realities of living with incurable cancer, and during her final days, made sure to document every moment, including her last Christmas ...